journal article·2024-01Open access

Development of 5-fluorouracil/etoposide co-loaded electrospun nanofibrous scaffold for localized anti-melanoma therapy

Shirin Shojaei, Mahtab Doostan, Hamidreza Mohammadi Motlagh, Seyedeh Sara Esnaashari, Hassan Maleki

Abstract

Nanofibrous scaffolds have emerged as promising candidates for localized drug delivery systems in the treatment of cutaneous cancers. In this study, we prepared an electrospun nanofibrous scaffold incorporating 5-fluorouracil (5-FU) and etoposide (ETP) for chemotherapy targeting melanoma cutaneous cancer. The scaffold was composed of polyvinyl alcohol (PVA) and chitosan (CS), prepared via the electrospinning process and loaded with the chemotherapeutic agents. We conducted relevant physicochemical characterizations, assessed cytotoxicity, and evaluated apoptosis against melanoma A375 cells. The prepared 5-FU/ETP co-loaded PVA/CS scaffold exhibited nanofibers (NFs) with an average diameter of 321 ± 61 nm, defect-free and homogenous morphology. FTIR spectroscopy confirmed successful incorporation of chemotherapeutics into the scaffold. Additionally, the scaffold demonstrated a hydrophilic surface, proper mechanical strength, high porosity, and efficient liquid absorption capacity. Notably, sustained and controlled drug release was observed from the nanofibrous scaffold. Furthermore, the scaffold significantly increased cytotoxicity (95%) and apoptosis (74%) in A375 melanoma cells. Consequently, the prepared 5-FU/ETP co-loaded PVA/CS nanofibrous scaffold holds promise as a valuable system for localized eradication of cutaneous melanoma tumors and mitigation of adverse drug reactions associated with chemotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Silk-based biomaterials and applications · Wound Healing and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Advanced Sciences and Technology, Department of Medical Nanotechnology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

Funding

Islamic Azad University

References (74)

Show source-provided references
1. 10.1007/s13671-023-00390-z10.1007/s13671-023-00390-z ↗
2. https://www.cancer.org/cancer/types/melanoma-skin-cancer/about/key-statistics
3. 10.1186/s12935-023-03012-710.1186/s12935-023-03012-7 ↗
4. 10.25259/IJDVL_1236_202110.25259/IJDVL_1236_2021 ↗
5. 10.1016/j.addr.2020.05.01110.1016/j.addr.2020.05.011 ↗
6. 10.1007/s42764-022-00090-110.1007/s42764-022-00090-1 ↗
7. 10.1016/j.canlet.2014.11.00110.1016/j.canlet.2014.11.001 ↗
8. 10.1007/s11912-022-01289-x10.1007/s11912-022-01289-x ↗
9. https://www.cancer.gov/about-cancer/treatment/drugs/skin
10. 10.2174/138161282666620082614044810.2174/1381612826666200826140448 ↗
11. Sabir F · Biointerface Res Appl Chem · 2021 · 11 · 11931
12. 10.3109/1061186X.2015.105104910.3109/1061186X.2015.1051049 ↗
13. 10.2147/IJN.S14631510.2147/IJN.S146315 ↗
14. 10.1186/s40580-019-0193-210.1186/s40580-019-0193-2 ↗
15. 10.3389/fphar.2023.133398610.3389/fphar.2023.1333986 ↗
16. 10.1080/15685551.2015.107050010.1080/15685551.2015.1070500 ↗
17. 10.1039/D0TB00271B10.1039/D0TB00271B ↗
18. Kumar L · Future J Pharmac Sci · 2021 · 7 · 110.1186/s43094-020-00150-x ↗
19. 10.3390/macromol401000410.3390/macromol4010004 ↗
20. 10.1007/s12274-024-6753-810.1007/s12274-024-6753-8 ↗
21. 10.18433/jpps2967410.18433/jpps29674 ↗
22. 10.1016/j.ajps.2018.04.00410.1016/j.ajps.2018.04.004 ↗
23. 10.1186/s12951-021-01065-210.1186/s12951-021-01065-2 ↗
24. 10.1002/pola.2776610.1002/pola.27766 ↗
25. 10.1016/j.ejmech.2023.11567610.1016/j.ejmech.2023.115676 ↗
26. 10.1186/s12918-017-0464-710.1186/s12918-017-0464-7 ↗
27. 10.1200/JCO.2011.37.641810.1200/JCO.2011.37.6418 ↗
28. 10.1007/s12672-023-00758-410.1007/s12672-023-00758-4 ↗
29. 10.1136/jitc-2021-00245910.1136/jitc-2021-002459 ↗
30. 10.1186/s12916-023-02852-410.1186/s12916-023-02852-4 ↗
31. 10.1016/j.eurpolymj.2023.11189810.1016/j.eurpolymj.2023.111898 ↗
32. 10.1016/j.jddst.2023.10437110.1016/j.jddst.2023.104371 ↗
33. 10.1016/j.drudis.2012.05.01010.1016/j.drudis.2012.05.010 ↗
34. 10.1016/j.jphotobiol.2017.08.03210.1016/j.jphotobiol.2017.08.032 ↗
35. 10.1016/j.ejps.2019.10500210.1016/j.ejps.2019.105002 ↗
36. Rojas J. · Excip Appl Formul Design Drug Deliv · 2015 · 569
37. 10.1039/C5RA01722J10.1039/C5RA01722J ↗
38. 10.1016/j.ijbiomac.2020.11.17410.1016/j.ijbiomac.2020.11.174 ↗
39. 10.1016/j.compositesb.2011.04.02410.1016/j.compositesb.2011.04.024 ↗
40. 10.3390/ma1612433210.3390/ma16124332 ↗
41. 10.3390/membranes1101003910.3390/membranes11010039 ↗
42. 10.1016/j.matdes.2024.11269410.1016/j.matdes.2024.112694 ↗
43. 10.1080/10601325.2024.232242710.1080/10601325.2024.2322427 ↗
44. 10.1016/j.jconrel.2020.01.02010.1016/j.jconrel.2020.01.020 ↗
45. 10.1016/j.heliyon.2023.e2371910.1016/j.heliyon.2023.e23719 ↗
46. 10.1016/j.ijpharm.2011.04.04210.1016/j.ijpharm.2011.04.042 ↗
47. 10.1016/j.msec.2017.03.19910.1016/j.msec.2017.03.199 ↗
48. 10.3390/nano1217293310.3390/nano12172933 ↗
49. 10.1016/j.ijbiomac.2019.05.20410.1016/j.ijbiomac.2019.05.204 ↗
50. 10.1016/j.ijbiomac.2019.05.09310.1016/j.ijbiomac.2019.05.093 ↗
51. 10.1016/j.ijbiomac.2016.04.07310.1016/j.ijbiomac.2016.04.073 ↗
52. 10.1016/j.ijbiomac.2013.08.05010.1016/j.ijbiomac.2013.08.050 ↗
53. 10.1186/s12951-023-01987-z10.1186/s12951-023-01987-z ↗
54. 10.3390/polym905016010.3390/polym9050160 ↗
55. 10.1016/j.ijpharm.2019.11848010.1016/j.ijpharm.2019.118480 ↗
56. Alotaibi BS · ACS Omega · 2024 · 9 · 12825
57. 10.1007/s12034-018-1709-910.1007/s12034-018-1709-9 ↗
58. 10.3390/polym1416326610.3390/polym14163266 ↗
59. 10.1002/jps.2406810.1002/jps.24068 ↗
60. 10.1208/s12249-024-02735-810.1208/s12249-024-02735-8 ↗
61. 10.1002/adv.2185010.1002/adv.21850 ↗
62. 10.1016/j.carbpol.2020.11631510.1016/j.carbpol.2020.116315 ↗
63. 10.1016/j.molcatb.2014.01.00510.1016/j.molcatb.2014.01.005 ↗
64. Patel P · Int J Life Sci Pharma Res · 2020 · 10
65. 10.4103/2230-973X.8596910.4103/2230-973X.85969 ↗
66. 10.1016/j.ijbiomac.2016.10.04210.1016/j.ijbiomac.2016.10.042 ↗
67. 10.1016/j.ijbiomac.2020.02.17610.1016/j.ijbiomac.2020.02.176 ↗
68. Eshkaraev S · World · 2021 · 6 · 49
69. 10.3390/polym1518383710.3390/polym15183837 ↗
70. 10.1111/j.1742-481X.2012.01077.x10.1111/j.1742-481X.2012.01077.x ↗
71. 10.2217/nnm-2017-001710.2217/nnm-2017-0017 ↗
72. 10.1007/s00289-021-03804-910.1007/s00289-021-03804-9 ↗
73. 10.1016/j.jddst.2023.10458210.1016/j.jddst.2023.104582 ↗
74. 10.1016/j.mtcomm.2020.10127610.1016/j.mtcomm.2020.101276 ↗